PHK
LRMR icon

Point72 Hong Kong’s Larimar Therapeutics LRMR Stock Holding History

Point72 Hong Kong’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-79
Closed -$3K – 1274
2019
Q1 		$3K Buy
79
+52
+193% +$2.67K ﹤0.01% 865
2018
Q4 		$2K Buy
+27
New +$2.67K ﹤0.01% 731
2018
Q3 		– Sell
-19
Closed -$2K – 1059
2018
Q2 		$2K Buy
+19
New +$1.61K ﹤0.01% 781

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Point72 Hong Kong's LRMR Position: Q2 2019 in Review

Point72 Hong Kong sold out of Larimar Therapeutics (LRMR) in Q2 2019, closing a stake of 79 shares — an estimated $3K sold.

Point72 Hong Kong first reported a position in LRMR in Q2 2018 and held it in 3 quarters. The position peaked at $3K in Q1 2019. 71 funds tracked by Wall St. Rank hold LRMR as of Q2 2019.

  • Point72 Hong Kong reported no remaining Larimar Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Point72 Hong Kong sold 79 Larimar Therapeutics shares in Q2 2019, an estimated $3K.
  • Point72 Hong Kong first reported a position in Larimar Therapeutics in Q2 2018 and held it in 3 quarters.
  • Point72 Hong Kong's Larimar Therapeutics position peaked at $3K in Q1 2019.
  • 71 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2019.

Based on Point72 Hong Kong's 13F filing for Q2 2019, filed 14 Aug 2019.